Find verified Mavacamten API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Mavacamten for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Mavacamten API.
Alternate Names: Camzyos, SAR-439152, QX45B99R3J
CAS No: 1642288-47-8
PubChem CID: 117761397
Mol Formula: C15H19N3O2
Mol Weight: 273.33 g/mol
IUPAC Name: 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
API Description: Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.
